Replies to post #19853 on Savvy Trades and Investments

[zenvesting]

No, I personally don't see much of a similarity between Biosyent and Vanc.

- Biosyent was profitable at a very early stage, Vanc is losing money at this point and it's hard to tell weather their aggressive growth plans will grow their revenues faster than their cash burn.
- Vanc is trying to tap into Biosyent's success with Feremax 150, but Biosyent has a much more rigorously tested and clinically proven product in Feremax 150 (formerly Niferex 150 in the U.S.).
- Feremax is a 150 mg dose of polysacharide iron with clinical data that proves it increases iron levels in patients. Vanc's Hema-Fer is a 12 mg dose and I don't see that they have any clinical studies to demonstrate what the product actually does for iron concentrations in humans.
- Biosyent has a much lower share count of ~14M and funded growth organically, there's no financials available for Vanc on Sedar, but they a presentation indicating 67 million fully diluted shares.